Investigation of the prognostic effects of inactivated parapoxvirus ovis and combined filgrastim therapy in naturally infected cats with feline panleukopenia virus

This study aimed to evaluate the effectiveness of adding inactivated parapoxvirus ovis (iPPVO) to standard treatment (ST), as well as the combination of ST + iPPVO + filgrastim, in cats infected with feline panleukopenia virus (FPV). The study involved four groups: a control group (Group A), an ST group (Group B), an ST + iPPVO + filgrastim group (Group C) and an ST + iPPVO group (Group D). The control group included 10 cats and each treatment group included 8 cats of various breeds and sexes, aged 0-10 months. To assess treatment efficacy, haematological parameters were analysed before and after therapy. Group C showed significantly higher levels of white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory response index (SIRI) compared to other groups. Group D demonstrated greater clinical and haematological improvement than Group B, ranking second after Group C. These findings suggest that the combined approach in Group C was the most effective, while the addition of iPPVO alone (Group D) also enhanced treatment outcomes. Furthermore, WBC, NEU, LYM, MON, NLR and SIRI appear to be valuable prognostic markers in feline panleukopenia, offering an insight into disease progression and therapeutic response.